ST天圣(002872) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥157,406,569.47, representing a 16.29% increase compared to ¥135,352,879.35 in the same period last year[5]. - The net loss attributable to shareholders was ¥15,891,842.97, a slight increase of 0.86% from a loss of ¥15,756,573.03 in the previous year[5]. - The net profit for the first quarter of 2023 was a loss of CNY 15,941,138.48, slightly improved from a loss of CNY 16,107,018.96 in the previous year[27]. - The total operating revenue for the first quarter of 2023 was CNY 157,406,569.47, an increase from CNY 135,352,879.35 in the same period last year, representing a growth of approximately 16.1%[26]. - The total operating costs for the first quarter of 2023 amounted to CNY 185,618,603.60, up from CNY 158,112,243.94, indicating an increase of about 17.5%[26]. - The total comprehensive income for the first quarter was -15,941,138.48 CNY, compared to -16,107,018.96 CNY in the previous period[28]. - Basic and diluted earnings per share were both -0.0500 CNY, slightly down from -0.0495 CNY in the previous period[28]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥41,342,239.54, a significant decline of 560.89% compared to a positive cash flow of ¥8,970,094.74 in the same period last year[5]. - Cash inflow from operating activities was 181,093,471.66 CNY, a decrease from 181,896,481.33 CNY year-over-year[30]. - Net cash outflow from operating activities was -41,342,239.54 CNY, compared to a positive inflow of 8,970,094.74 CNY in the previous period[31]. - Cash inflow from investing activities totaled 16,514,150.00 CNY, significantly down from 130,424,863.54 CNY in the previous period[31]. - Net cash outflow from investing activities was -49,364,825.51 CNY, compared to -91,517,616.88 CNY in the previous period[31]. - Cash inflow from financing activities was 169,800,000.00 CNY, up from 47,000,000.00 CNY in the previous period[31]. - Net cash inflow from financing activities was 85,321,749.71 CNY, compared to 12,815,643.92 CNY in the previous period[31]. - The ending cash and cash equivalents balance was 272,865,094.73 CNY, down from 299,103,683.75 CNY at the beginning of the period[31]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,980,922,616.16, showing a 0.37% increase from ¥2,969,827,475.68 at the end of the previous year[5]. - The total assets as of March 31, 2023, were CNY 2,980,922,616.16, compared to CNY 2,969,827,475.68 at the start of the year[25]. - The total liabilities increased to CNY 808,103,736.09 from CNY 782,234,793.97, reflecting a rise of approximately 3.3%[25]. - The company's cash and cash equivalents at the end of the first quarter were CNY 272,865,094.74, down from CNY 278,250,410.08 at the beginning of the year[23]. Borrowings and Financial Expenses - Short-term borrowings increased by 40.32% compared to the end of the previous year, primarily due to the reapplication for bank loans[9]. - The company reported a significant decrease in short-term borrowings, which rose to CNY 125,431,995.83 from CNY 89,393,118.06, indicating a rise of approximately 40.4%[25]. - The company's financial expenses decreased, while interest income increased due to the recognition of interest income from financial support provided to Changsheng Pharmaceutical[12]. Research and Development - The company's technology center was recognized as a National Enterprise Technology Center, enhancing its research and development capabilities[20]. - Research and development expenses for the first quarter were CNY 8,257,754.73, compared to CNY 7,291,377.71 in the previous year, showing an increase of about 13.3%[27]. Government Support and Investment Income - The company received government subsidies amounting to ¥4,611,341.12 during the reporting period, which contributed to its non-recurring gains[6]. - The company reported a 95.13% decrease in investment income compared to the previous year, primarily due to the lack of maturity of financial products during the reporting period[14]. Other Information - The weighted average return on net assets was -0.73%, slightly lower than -0.70% in the same period last year[5]. - The first quarter report was not audited[32]. - The company's inventory at the end of the first quarter was CNY 126,619,887.21, down from CNY 130,873,102.95 at the beginning of the year, reflecting a decrease of about 3.3%[24]. - The company plans to participate in the national drug centralized procurement, with its product Furosemide injection expected to win the bid[21].